| Digestive Disease Care, Pc | |
|
235 N Belle Mead Rd East Setauket NY 11733-3538 | |
| (631) 450-1500 | |
| (347) 236-3163 |
| Full Name | Digestive Disease Care, Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 235 N Belle Mead Rd, East Setauket, New York |
| Authorized Official Name and Position | Nilesh Mehta (DOCTOR) |
| Authorized Official Contact | 6462811103 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Digestive Disease Care, Pc 235 N Belle Mead Rd East Setauket NY 11733-3538 Ph: (631) 450-1500 | Digestive Disease Care, Pc 235 N Belle Mead Rd East Setauket NY 11733-3538 Ph: (631) 450-1500 |
| NPI Number | 1184871774 |
|---|---|
| Provider Enumeration Date | 08/26/2008 |
| Last Update Date | 09/22/2023 |
| Medicare PECOS PAC ID | 7113093071 |
|---|---|
| Medicare Enrollment ID | O20080829000434 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184871774 | NPI | - | NPPES |
| Provider Name | Ilya Badalov |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1679543888 PECOS PAC ID: 0941193536 Enrollment ID: I20040206000260 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Elena I Raftopol |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1497838460 PECOS PAC ID: 9931091691 Enrollment ID: I20040326001127 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Andrew Blank |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1346233475 PECOS PAC ID: 4587626114 Enrollment ID: I20041027000393 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Philip Q Xiao |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1710928163 PECOS PAC ID: 7517929623 Enrollment ID: I20041101000899 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Hillary Diamond |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902967011 PECOS PAC ID: 1052362639 Enrollment ID: I20050201001009 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Shirley Johnson Hall |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1265591952 PECOS PAC ID: 8820030851 Enrollment ID: I20050531000625 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Gregg M Szerlip |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1629128780 PECOS PAC ID: 7012934888 Enrollment ID: I20051031000943 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Sharda Ramsaroop |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043290208 PECOS PAC ID: 8426060559 Enrollment ID: I20060608000052 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Nanda Ramsaroop |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922048032 PECOS PAC ID: 4789781659 Enrollment ID: I20070530000108 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Preeti Mehta |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1134335946 PECOS PAC ID: 9830285634 Enrollment ID: I20071009000846 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Shah M Giashuddin |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1538370929 PECOS PAC ID: 4183710783 Enrollment ID: I20071012000033 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Susan N Ramdhaney |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1134206345 PECOS PAC ID: 1759468341 Enrollment ID: I20080407000467 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Lobina K Kalam |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1801952981 PECOS PAC ID: 4183795206 Enrollment ID: I20080618000090 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Jianhong J Zhou |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1386848778 PECOS PAC ID: 5092882969 Enrollment ID: I20080918000035 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Daphna Raquel Barasch |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902061146 PECOS PAC ID: 2668549874 Enrollment ID: I20080930000097 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Syeda Tanzia Hossain |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1891816245 PECOS PAC ID: 0749358240 Enrollment ID: I20081010000516 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Nathan D Schulman |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1134296866 PECOS PAC ID: 9830249465 Enrollment ID: I20090603000007 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Jay G Merker |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1508933250 PECOS PAC ID: 7911057542 Enrollment ID: I20090603000010 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Stewart A Robbins |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1841367588 PECOS PAC ID: 2769532381 Enrollment ID: I20090603000056 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Alan R Sandberg |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1982706446 PECOS PAC ID: 6608967815 Enrollment ID: I20090812000316 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Biju Abraham |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1104059427 PECOS PAC ID: 7214083047 Enrollment ID: I20090921000453 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Nilesh Mehta |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1649436163 PECOS PAC ID: 0345389607 Enrollment ID: I20091125000405 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Zvika J. Schreiber |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1891966693 PECOS PAC ID: 1850585407 Enrollment ID: I20101028000202 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | David H Oustecky |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1952547945 PECOS PAC ID: 1658535836 Enrollment ID: I20120620000185 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Leena Sayedy |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1184802274 PECOS PAC ID: 0547419053 Enrollment ID: I20120927000000 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Antonio L Galvao Neto |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1255469250 PECOS PAC ID: 3971658063 Enrollment ID: I20121105000522 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Thomas E Costello |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1093957342 PECOS PAC ID: 2264673128 Enrollment ID: I20130719000184 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Aqeel Ahmed |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1538300991 PECOS PAC ID: 7012054356 Enrollment ID: I20130923000145 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Merajur Rahman |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891010732 PECOS PAC ID: 9335362516 Enrollment ID: I20140515000003 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Ashraf Mikhail |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851570303 PECOS PAC ID: 9335209493 Enrollment ID: I20140515000406 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Melissa R Kang |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1700048154 PECOS PAC ID: 5193999464 Enrollment ID: I20151007003059 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Sadra Azizi-ghannad |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1639435084 PECOS PAC ID: 0446542872 Enrollment ID: I20160706000451 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Maria Uliano |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659783587 PECOS PAC ID: 5890066930 Enrollment ID: I20170808000186 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Eric Yoon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750624532 PECOS PAC ID: 0244597276 Enrollment ID: I20171130000083 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Uma Narayana |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023537255 PECOS PAC ID: 4183982994 Enrollment ID: I20180813001190 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Michael H Liu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528319480 PECOS PAC ID: 8820332091 Enrollment ID: I20181129002116 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Josie Joy T Go |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598183295 PECOS PAC ID: 1759626336 Enrollment ID: I20201216001973 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Beulah Anne Abraham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659803237 PECOS PAC ID: 9234476334 Enrollment ID: I20210204002754 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Brooks Ryan Crowe |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1174979272 PECOS PAC ID: 7911298468 Enrollment ID: I20220822001220 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Christine Chen |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1578918769 PECOS PAC ID: 4688912256 Enrollment ID: I20221028002250 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Brittany Grace Rodriguez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710763180 PECOS PAC ID: 5193173664 Enrollment ID: I20231121002962 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
| Provider Name | Khushbu Raza |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447870084 PECOS PAC ID: 6507215340 Enrollment ID: I20231206000231 |
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
News Archive
iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
Work these days can certainly be stressful, and that stress can eventually lead to burnout and even health problems. But can the growing number of wellness programs at work make employees healthier than they would otherwise be? According to recent research, such programs around the country save $1.9 trillion in health care costs per year. Makes sense, since a large portion of health care costs are spent treating preventable conditions.
In an age when microbial pathogens are growing increasingly resistant to the conventional antibiotics used to tamp down infection, a team of Wisconsin scientists has synthesized a potent new class of compounds capable of curbing the bacteria that cause staph infections.
› Verified 9 days ago
Eastern Long Island Family Medicine Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 100 S Jersey Ave, Suite 14, East Setauket, NY 11733 Phone: 631-751-3883 Fax: 631-751-3909 | |
L&l Holistic Healing, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6 S Jersey Ave, East Setauket, NY 11733 Phone: 516-605-4868 | |
Long Island Digestive Disease Consultants, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3400 Nesconset Hwy, Ste 101, East Setauket, NY 11733 Phone: 631-751-8700 Fax: 631-751-5971 | |
North Suffolk Family Medical Care Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4 Technology Dr, Suite 210, East Setauket, NY 11733 Phone: 631-331-1506 Fax: 631-331-1705 | |
Unique You Medical Wellness Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8 Technology Drive, Suite 104, East Setauket, NY 11733 Phone: 516-704-7447 | |
Setauket Medical, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4 Technology Dr, Suite 220, East Setauket, NY 11733 Phone: 631-964-9581 Fax: 631-476-9298 |